NERV Description — Minerva Neurosciences Inc
Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on the development and commercialization of product candidates to treat patients suffering from central nervous system diseases. Co.'s primary product candidate is roluperidone, a compound it is developing for the treatment of negative symptoms in patients with schizophrenia. Co. holds the license to roluperidone from Mitsubishi Tanabe Pharma Corporation with the rights to develop, sell and import roluperidone globally, excluding most of Asia. Co. also has exclusive rights to develop and commercialize MIN-301, a compound for the treatment of Parkinson's disease.